news – Page 16 – Medxy AI

Diabetes & Endocrinology news Public Health

The Sweet Tooth Trial: Evidence Challenges the Assumption That Lowering Exposure Reduces Sweet Taste Liking

By MedXY 02/04/2026

A 6-month randomized controlled trial reveals that varying dietary sweet taste exposure does not alter sweet taste liking, energy intake, or body weight, questioning the efficacy of public health recommendations to reduce sweet exposure for palate retraining.

Diabetes & Endocrinology Internal Medicine news

Once-Weekly Insulin GZR4: A Potential Paradigm Shift in Basal Insulin Therapy for Type 2 Diabetes

By MedXY 02/04/2026

A Phase 1b trial demonstrates that the once-weekly insulin GZR4 is safe, well-tolerated, and effective in lowering FPG and HbA1c in patients with T2DM, potentially offering a more convenient alternative to daily basal insulin.

Cardiology news

FFR-Guided PCI Demonstrates Decade-Long Superiority Over Medical Therapy in Stable CAD: The FAME 2 Trial

By MedXY 02/04/2026

The 11-year FAME 2 trial results confirm that FFR-guided PCI significantly improves outcomes for stable CAD patients with functionally significant lesions, primarily by reducing urgent revascularizations, reinforcing the importance of physiological assessment in revascularization decisions.

Cardiology Diabetes & Endocrinology news

GLP-1 Receptor Agonists Associated with Lower Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients

By MedXY 02/04/2026

This real-world study demonstrates that GLP-1 receptor agonists significantly reduce AF recurrence, progression to permanent AF, and cardiovascular hospitalizations in obese patients following catheter ablation, highlighting their role as a critical adjunctive therapy in metabolic-arrhythmic management.

Diabetes & Endocrinology Internal Medicine news

Beyond Glycemic Control: How SGLT2 and DPP-4 Inhibitor Combinations Rescue the Urinary Microbiome in Type 2 Diabetes

By MedXY 02/04/2026

A new study reveals that combining Empagliflozin with Linagliptin reverses urinary dysbiosis in T2D patients, potentially reducing the risk of urogenital infections and improving treatment adherence compared to SGLT2 inhibitor monotherapy.

Cardiology news

Bridging the Gap: Why In-Procedure QFR Variability May Explain the FAVOR III Europe Outcomes

By MedXY 02/04/2026

The REPEAT-QFR study reveals modest agreement between in-procedure and core laboratory quantitative flow ratio (QFR) measurements, suggesting that angiographic quality and user adherence significantly impact diagnostic accuracy.

Diabetes & Endocrinology news Public Health

Challenging Public Health Dogma: Six Months of Low Sweet Taste Exposure Fails to Shift Preference or Weight

By MedXY 02/04/2026

The Sweet Tooth Trial reveals that reducing dietary sweet exposure for six months does not decrease sweet taste liking, calorie intake, or weight, questioning the efficacy of current public health strategies centered solely on reducing sweet-tasting food exposure.

Cardiology news

FFR-Guided PCI Demonstrates Decade-Long Superiority Over Medical Therapy in Stable Coronary Artery Disease

By MedXY 02/04/2026

An 11-year follow-up of the FAME 2 trial reveals that FFR-guided PCI significantly outperforms medical therapy alone in patients with hemodynamically significant stenoses, primarily by reducing urgent revascularizations, with a favorable win ratio of 1.25.

Cardiology Diabetes & Endocrinology news

Circadian Heart Rate Fluctuations: A Potent 21-Year Predictor of Mortality in Patients with Diabetes

By MedXY 02/04/2026

A 21-year longitudinal study demonstrates that impaired circadian heart rate fluctuations, measured via 24-hour ambulatory monitoring, significantly predict cardiovascular and all-cause mortality in diabetes, offering a low-cost, accessible tool for identifying high-risk patients.

Cardiology Diabetes & Endocrinology news

Haptoglobin Levels and Phenotype as Determinants of Cardiovascular Risk in Type 2 Diabetes: Insights from the FIELD Sub-study

By MedXY 02/04/2026

This FIELD sub-study reveals that while Haptoglobin 1-1 phenotype combined with low HP levels indicates the lowest CVD risk in Type 2 Diabetes, higher HP levels significantly increase risk, particularly within the HP 1-1 group. Fenofibrate benefits appear independent of HP status.

Cardiology Diabetes & Endocrinology news

Beyond Blood Sugar: Why Insulin Resistance Drives Vagal Dysfunction in Heart Failure

By MedXY 02/04/2026

Evidence from the Myovasc study reveals that insulin resistance and C-peptide levels are independent predictors of impaired cardiac vagal activity in heart failure, suggesting that metabolic health directly influences autonomic regulation beyond simple glycemic control.

news Pediatrics Public Health

Curbing the Industrial Diet: School-Based Intervention Reduces Adolescent Ultra-Processed Food Intake by 1,000 Kcal Per Day

By MedXY 02/04/2026

A cluster-randomised trial in India demonstrates that a school-based behavior change intervention significantly reduces ultra-processed food consumption among adolescents, offering a scalable model for public health strategies in low- and middle-income countries.

Diabetes & Endocrinology Internal Medicine news

Can We Predict Who Benefits? Baseline Insulin Secretion as a Gatekeeper for Abatacept Efficacy in Stage 1 T1D

By MedXY 02/04/2026

A post-hoc analysis demonstrates that baseline insulin secretion identifies responders to abatacept in Stage 1 T1D. High-secretors experienced a 15.8-month delay in disease progression and a 54% reduction in risk, providing the first evidence of successful immune intervention in the earliest stage of the disease.

Gastroenterology Internal Medicine news

Metopimazine Mesylate (NG101) for Gastroparesis: Evaluating the Gap Between Patient Global Impression and Symptom Severity Scores

By MedXY 02/04/2026

A Phase 2 trial of NG101 for gastroparesis missed its primary endpoint for nausea severity on the DIGS-DD scale but demonstrated significant improvements in Patient Global Impression of Change (PGIC) and a favorable safety profile, particularly in idiopathic cases.

Diabetes & Endocrinology Nephrology news

Beyond Glycemic Control: Empagliflozin/Linagliptin Combination Restores Urinary Microbiota Homeostasis in Type 2 Diabetes

By MedXY 02/03/2026

A randomized clinical study demonstrates that while SGLT2 inhibitors alone may induce urinary dysbiosis and increase pathogen risk, combining them with DPP-4 inhibitors restores a healthy urinary microbiota, potentially improving patient compliance and long-term therapeutic outcomes.

Cardiology news

Bridging the Gap: Understanding In-Procedure Variability and Quality Control in the FAVOR III Europe QFR Analysis

By MedXY 02/03/2026

The REPEAT-QFR study reveals a modest 72% diagnostic agreement between bedside and core-lab QFR. The findings underscore that angiographic quality and strict adherence to standard operating procedures are essential for accurate, non-invasive coronary physiology assessment in clinical practice.

Cardiology Diabetes & Endocrinology news

Diminished Circadian Heart Rate Fluctuations: A Potent Predictor of 21-Year Mortality in Patients with Diabetes

By MedXY 02/03/2026

A 21-year longitudinal study reveals that blunted circadian heart rate variability and nocturnal dipping are independent predictors of cardiovascular and all-cause mortality in type 1 and type 2 diabetes, offering a low-cost risk stratification tool via ambulatory monitoring.

Cardiology Diabetes & Endocrinology news

Haptoglobin 1-1 and Low Protein Levels: Identifying the Lowest Cardiovascular Risk in Type 2 Diabetes

By MedXY 02/03/2026

A FIELD sub-study reveals that while higher haptoglobin levels increase cardiovascular risk—particularly in those with the HP 1-1 phenotype—fenofibrate's protective effects remain consistent regardless of haptoglobin status, challenging previous assumptions about phenotype-specific treatment responses.

Cardiology Diabetes & Endocrinology news

Insulin Metabolism as a Primary Driver of Cardiac Autonomic Dysfunction in Heart Failure: Insights from the Myovasc Study

By MedXY 02/03/2026

The Myovasc study demonstrates that insulin resistance and secretion markers, rather than glucose levels alone, are independently associated with impaired cardiac vagal activity in heart failure patients, suggesting a metabolic-autonomic axis that requires targeted clinical attention.

news Pediatrics Public Health

School-Based Interventions Achieve Dramatic Reduction in Ultra-Processed Food Consumption Among Indian Adolescents

By MedXY 02/03/2026

A cluster-randomised trial in India demonstrates that a 6-month school-based behavioural intervention significantly reduces ultra-processed food consumption among adolescents by over 1000 Kcal/day, highlighting a scalable strategy to combat the rising burden of diet-related non-communicable diseases in low- and middle-income countries.